59108-13-3 Usage
Uses
Used in Pharmaceutical Industry:
5,7-DICHLORO-4-HYDROXY-2-(TRIFLUOROMETHYL)QUINOLINE is used as a key intermediate in the synthesis of various pharmaceuticals for its antimicrobial and antifungal properties, contributing to the development of new drugs that combat resistant infections.
Used in Agrochemical Industry:
In the agrochemical sector, 5,7-DICHLORO-4-HYDROXY-2-(TRIFLUOROMETHYL)QUINOLINE is used as a component in the formulation of agricultural pesticides, leveraging its strong antimicrobial and antifungal properties to protect crops from diseases and pests.
Used in Organic Synthesis:
5,7-DICHLORO-4-HYDROXY-2-(TRIFLUOROMETHYL)QUINOLINE is used as a building block in organic synthesis, particularly for the production of fluorinated compounds, which have a wide range of applications in various chemical and pharmaceutical processes.
Used in Materials Science:
In the field of materials science, 5,7-DICHLORO-4-HYDROXY-2-(TRIFLUOROMETHYL)QUINOLINE is used for the development of novel fluorescent dyes and optical materials, taking advantage of its unique chemical structure and properties to create innovative materials with specific optical characteristics.
Check Digit Verification of cas no
The CAS Registry Mumber 59108-13-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,9,1,0 and 8 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 59108-13:
(7*5)+(6*9)+(5*1)+(4*0)+(3*8)+(2*1)+(1*3)=123
123 % 10 = 3
So 59108-13-3 is a valid CAS Registry Number.
InChI:InChI=1/C7H4BrFO/c8-7-3-6(9)2-1-5(7)4-10/h1-4H
59108-13-3Relevant academic research and scientific papers
Structure-Activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating mycobacterium tuberculosis
Lilienkampf, Annamaria,Jialin, Mao,Baojie, Wan,Yuehong, Wang,Franzblau, Scott G.,Kozikowski, Alan P.
supporting information; experimental part, p. 2109 - 2118 (2009/12/31)
Tuberculosis (TB) remains as a global pandemic that is aggravated by a lack of health care, the spread of HIV, and the emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDRTB) strains. New anti-TB drugs are urgently required to shorten the long 6-12 month treatment regimen and to battle drug-resistant Mtb strains. We have identified several potent quinoline-based anti-TB compounds, bearing an isoxazole containing side-chain. The most potent compounds, 7g and 13, exhibited submicromolar activity against the replicating bacteria (R-TB), with minimum inhibitory concentrations (MICs) of 0.77 and 0.95 μM, respectively. In general, these compounds also had micromolar activity against the nonreplicating persistent bacteria (NRP-TB) and did not show toxicity on Vero cells up to 128 μM concentration. Compounds 7g and 13 were shown to retain their anti-TB activity against rifampin, isoniazid, and streptomycin resistant Mtb strains. The results suggest that quinoline-isoxazole-based anti-TB compounds are promising leads for new TB drug development.
